Translational research of "A multicenter Phase II basket study of Brigatinib in patients with ALK fusion gene-positive advanced/recurrent solid tumors"

Translational research of "A multicenter Phase II basket study of Brigatinib in patients with ALK fusion gene-positive advanced/recurrent solid tumors" - WJOG15221MTR

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000047903

Enrollment

Registered

2022-06-01

Start date

2022-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALK fusion gene positive advanced/recurrent solid tumors except for non-small cell lung cancer

Interventions

Explore biomarkers for therapeutic efficacy and resistance mechanisms of brigtinib in ALK fusion gene-positive advanced or recurrent solid tumors using tumor tissue and blood samples

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients enrolled in the "multicenter phase II basket study of brigatinib in patients with ALK fusion gene positive advanced/recurrent solid tumors" who would provide written consent for the study will be eligible.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To explore biomarkers for therapeutic efficacy and resistance mechanisms of brigatinib therapy in patients with Anaplastic lymphoma kinase (ALK) fusion gene positive solid tumors.	—

Countries

Japan

Contacts

Public ContactKen Mizushima

West Japan Oncology Group Secretariat

mizushima@wjog.jp06-6633-7400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Translational research of &quot;A multicenter Phase II basket study of Brigatinib in patients with ALK fusion gene-positive advanced/recurrent solid tumors&quot;